Combined Steroid Composition for Sustained COVID-19 Symptom Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for COVID-19, such as high-dose dexamethasone, lead to side effects like immunosuppression and secondary pneumonia, while treatments for mild to moderate symptoms are ineffective, posing a challenge in managing symptoms effectively without adverse reactions.
Innovation Solution
A composition combining dexamethasone with triamcinolone acetonide, sodium chloride, benzyl alcohol, carboxymethylcellulose sodium, and polysorbate 80, administered via injection, provides sustained relief without the need for weaning down steroid doses, using triamcinolone's sustained-release properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If high-dose dexamethasone is administered to treat COVID-19, then inflammation is reduced, but immunosuppression and secondary pneumonia occur
Solution Approach 1:
The patent divides the steroid treatment into two distinct components: dexamethasone (for rapid anti-inflammatory effect) and triamcinolone acetonide (for sustained-release effect). This segmentation allows each steroid to perform its specific function without the harmful cumulative effects of high-dose single-steroid treatment, thereby reducing inflammation while minimizing immunosuppression.
Solution Approach 2:
The patent creates a composite steroid formulation combining dexamethasone and triamcinolone acetonide in specific proportions. This composite approach leverages the immediate efficacy of dexamethasone and the prolonged action of triamcinolone acetonide, achieving sustained anti-inflammatory effect at lower overall doses, thus preventing both inflammation and immunosuppression.
2Reliability
If high-dose dexamethasone is administered, then severe symptoms are treated, but weaning down is required to avoid adrenal crisis and hypotension
Solution Approach 1:
The patent incorporates triamcinolone acetonide, a sustained-release steroid, which预先 (in advance) provides prolonged steroid coverage. This preliminary action eliminates the need for gradual weaning down, as the sustained-release component maintains therapeutic levels throughout the treatment period, simplifying the treatment protocol and avoiding adrenal crisis.
3Reliability
If Nirmatrelvir/ritonavir is administered, then viral replication is inhibited, but it is ineffective in patients with mild to moderate symptoms
Solution Approach 1:
The patent creates a universal steroid formulation that can be effectively applied across all symptom severities (mild, moderate, and severe COVID-19 cases). The combination of dexamethasone and triamcinolone acetonide provides adaptable anti-inflammatory coverage that works regardless of disease severity, unlike antivirals that show efficacy only in specific symptom ranges.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively alleviates symptoms in patients with mild to severe COVID-19, reducing side effects and ensuring continuous symptom relief over several days.
Implementation Method 1
The combined composition includes two steroids to alleviate the need for weaning down following the administration of dexamethasone, thereby reducing the side effects caused by high doses of dexamethasone
Data Source
AI summary
A composition for the treatment of COVID-19 is disclosed, including a first composition including approximately 10 mg of dexamethasone. The first composition is combined with a second composition including between approximately 48 mg to approximately 80 mg of triamcinolone acetonide, sodium chloride, benzyl alcohol, carboxymethylcellulose sodium, and polysorbate 80.